Oral GLP-1s in 2025: Orforglipron and Oral Semaglutide Evidence
What 2025 trials showed about oral GLP-1 options — orforglipron (ATTAIN program) and high-dose oral semaglutide (OASIS-4) — and what they mean for patients.
Do oral GLP-1 pills work for weight loss?
Yes, recent 2025 trials show oral GLP-1s can produce meaningful weight loss. In ATTAIN-1 (New England Journal of Medicine, 2025), the investigational once-daily pill orforglipron produced about 11–12% average weight loss over 72 weeks; OASIS-4 (2025) reported about 13.6% with high-dose oral semaglutide. These are promising but were not all FDA-approved at the time of writing.
Disclaimer: American Telehealth Review is an editorial resource and does not provide medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.
The 2025 oral evidence
ATTAIN-1 and ATTAIN-2 evaluated orforglipron in obesity and in type 2 diabetes, showing class-consistent efficacy and gastrointestinal side effects. OASIS-4 studied oral semaglutide 25 mg. Oral options may improve access for patients who prefer pills over injections.
What patients should know
Investigational and newly studied medicines are not the same as compounded products sold online today. Approval status, dosing, and availability change; rely on a licensed clinician and verify what a telehealth program actually prescribes.
Mean weight loss in pivotal GLP-1 trials
| Medication | Trial (year) | Mean weight loss |
|---|---|---|
| Tirzepatide 15 mg | SURMOUNT-1 (2022) | 20.9% |
| Tirzepatide | SURMOUNT-5 (2025) | 20.2% |
| Semaglutide 2.4 mg | STEP 1 (2021) | 14.9% |
| Semaglutide 2.4 mg | SURMOUNT-5 (2025) | 13.7% |
| Oral semaglutide 25 mg | OASIS-4 (2025) | 13.6% |
| Oral orforglipron 36 mg | ATTAIN-1 (2025) | 12.4% |
Data shown in the chart above. Compounded versions are not the FDA-approved products studied in these trials.
Frequently asked questions
Are GLP-1 pills as effective as injections?
2025 oral trials show meaningful weight loss (about 11–14%), though injectable tirzepatide produced more in head-to-head data. Effectiveness and approval status vary.
Can I buy oral orforglipron now?
Approval and availability evolve; confirm current status and never use research-labeled products. Compounded products are not FDA-approved.
Sources
- ATTAIN-1 Trial Investigators. Oral orforglipron for obesity. N Engl J Med. 2025.
- ATTAIN-2 Trial Investigators. Oral orforglipron in type 2 diabetes. Lancet. 2025.
- OASIS-4 Investigators. Oral semaglutide 25 mg for obesity. 2025.
- U.S. FDA — Medications containing semaglutide and tirzepatide; Compounding and the FDA (fda.gov).